Publication:
Remote Ischemic Conditioning for Anthracycline Cardiotoxicity: The Need to Protect the Most Vulnerable.

Simple item page
dc.contributor.authorIbáñez, Borja
dc.contributor.authorGomes-Silva, Maria
dc.contributor.funderUnión Europea. Comisión Europea. H2020es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderFundación ProCNICes_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España)es_ES
dc.contributor.funderAstraZenecaes_ES
dc.contributor.funderJanssen Cilages_ES
dc.contributor.funderGilead Sciences (Spain)es_ES
dc.contributor.funderMerck, Sharp & Dohmees_ES
dc.contributor.funderBristol-Myers Squibbes_ES
dc.contributor.funderRochees_ES
dc.contributor.funderNovartises_ES
dc.contributor.funderADC Therapeuticses_ES
dc.contributor.funderAbbViees_ES
dc.date.accessioned2023-09-13T09:17:12Z
dc.date.available2023-09-13T09:17:12Z
dc.date.issued2023-06
dc.description.abstract[Figure: see text]es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipDrs Ibáñez and Gomes-Silva are funded by the European Commission (H2020-HEALTH “RESILIENCE”, grant number 945118). Dr Ibáñez is recipient of an ERC-CoG (grant number 819775) and has received funds from the Spanish Ministry of Science and Innovation (PID2019- 110369RB-I00), and from the Comunidad de Madrid (S2022/BMD-7403, RENIM-CM). The CNIC is supported by the ISCIII, the Ministry of Science and Innovation, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S). Dr. Gomes-Silva has received grants from Astrazeneca; has received advisory board payments from Janssen, Gilead Sciences, Merck Sharp and Dohme, Bristol Myers Squibb, Roche, Takeda, Novartis, and ADC Therapeutics; and has received travel support from Roche, Janssen, Abbvie, Gilead, Takeda (all unrelated to the content of this paper).es_ES
dc.format.number3es_ES
dc.format.page356es_ES
dc.format.volume5es_ES
dc.identifier.citationJACC CardioOncol. 2023 Jun 20;5(3):356-359.es_ES
dc.identifier.doi10.1016/j.jaccao.2023.05.002es_ES
dc.identifier.e-issn2666-0873es_ES
dc.identifier.journalJACC. CardioOncologyes_ES
dc.identifier.pubmedID37397082es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16458
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/S2022/BMD-7403/RENIM-CM/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-110369RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CEX2020-001041-Ses_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/RESILIENCE/945118es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/ERC-CoG/819775es_ES
dc.relation.publisherversion10.1016/j.jaccao.2023.05.002es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleRemote Ischemic Conditioning for Anthracycline Cardiotoxicity: The Need to Protect the Most Vulnerable.es_ES
dc.typeeditoriales_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication2cac8bb6-2bff-4bf6-8209-bdbd21781786
relation.isAuthorOfPublication.latestForDiscovery2cac8bb6-2bff-4bf6-8209-bdbd21781786

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Remote Ischemic_JACC CardioOncol_2023.pdf
Size:
137.13 KB
Format:
Adobe Portable Document Format
Description:
Editorial Material
Download

Collections

Grupos de investigación